Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives
EN Imyanitov, AG Iyevleva, EV Levchenko - Critical reviews in oncology …, 2021 - Elsevier
Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …
Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives
EN Imyanitov, AG Iyevleva… - Critical reviews in …, 2021 - pubmed.ncbi.nlm.nih.gov
Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …
Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives.
EN Imyanitov, AG Iyevleva… - Critical Reviews in …, 2020 - europepmc.org
Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …
[引用][C] Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives
EN Imyanitov, AG Iyevleva, EN Levchenko - Critical Reviews in Oncology …, 2021 - elibrary.ru